Exicure Inc. (XCUR), an early-stage biotechnology company, announced on Thursday a co-development agreement with Korean biotechnology company Adbiotech Co. Ltd., for combination therapies with Burixafor in treating haematological indications.
Burixafor (GPC-100) is an investigational drug developed to treat varied indications such as sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors. It previously completed a successful Phase 2 clinical trial for multiple myeloma, and is currently being explored for other haematological indications.
As part of the agreement, Adbiotech will conduct in vitro studies for preclinical validation and translational research, while Exicure is expected to lead clinical and regulatory strategy for the drug's development.
The companies are directing efforts toward studies enabling an investigational new drug (IND) submission for burixafor.
XCUR is currently trading at $3.64, up 0.05%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.